145 related articles for article (PubMed ID: 32256703)
1. Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population.
Lago NM; Villar MV; Ponte RV; Nallib IA; Alvarez JJC; López JRA; López RL; Iruegas MEP
Ecancermedicalscience; 2020; 14():1020. PubMed ID: 32256703
[TBL] [Abstract][Full Text] [Related]
2. Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma.
Nakayama I; Takahari D; Chin K; Wakatsuki T; Takamatsu M; Yamamoto N; Ogura M; Ooki A; Fukuda K; Osumi H; Fukuoka S; Shinozaki E; Yamaguchi K
ESMO Open; 2023 Aug; 8(4):101582. PubMed ID: 37348349
[TBL] [Abstract][Full Text] [Related]
3. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.
Shan L; Ying J; Lu N
Diagn Pathol; 2013 May; 8():76. PubMed ID: 23656792
[TBL] [Abstract][Full Text] [Related]
4. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population.
Roy PS; Nyodu T; Hazarika M; Saikia BJ; Bhuyan C; Inamdar A; Nyuthe CW; Borthakur B; Sharma JD
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1139-1145. PubMed ID: 31030487
[TBL] [Abstract][Full Text] [Related]
7. Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India.
Nadaf AS; Rani H; Dinesh US
Asian Pac J Cancer Prev; 2018 May; 19(5):1381-1385. PubMed ID: 29802704
[TBL] [Abstract][Full Text] [Related]
8. The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel.
Bar-Sela G; Hershkovitz D; Haim N; Kaidar-Person O; Shulman K; Ben-Izhak O
Oncol Lett; 2013 Feb; 5(2):559-563. PubMed ID: 23420289
[TBL] [Abstract][Full Text] [Related]
9. HER2 Expression in Gastric and Gastroesophageal Cancer: Report from a Tertiary Care Hospital in North India.
Tewari M; Kumar A; Mishra RR; Kumar M; Shukla HS
Indian J Surg; 2015 Dec; 77(Suppl 2):447-51. PubMed ID: 26730043
[TBL] [Abstract][Full Text] [Related]
10. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.
Janjigian YY; Werner D; Pauligk C; Steinmetz K; Kelsen DP; Jäger E; Altmannsberger HM; Robinson E; Tafe LJ; Tang LH; Shah MA; Al-Batran SE
Ann Oncol; 2012 Oct; 23(10):2656-2662. PubMed ID: 22689179
[TBL] [Abstract][Full Text] [Related]
11. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A; Arrazubi V; Hernandez R; Cano JM; Custodio A; Pericay Pijaume C; Aguado G; Martínez Lago N; Sánchez Cánovas M; Cacho Lavin D; Visa L; Martinez-Torron A; Arias-Martinez A; López F; Limón ML; Vidal Tocino R; Fernández Montes A; Alsina M; Pimentel P; Reguera P; Martín Carnicero A; Ramchandani A; Granja M; Azkarate A; Martín Richard M; Serra O; Hernández Pérez C; Hurtado A; Gil-Negrete A; Sauri T; Morales Del Burgo P; Gallego J
Gastric Cancer; 2021 Jul; 24(4):926-936. PubMed ID: 33651195
[TBL] [Abstract][Full Text] [Related]
12. HER2 in resected gastric cancer: Is there prognostic value?
Fisher SB; Fisher KE; Squires MH; Patel SH; Kooby DA; El-Rayes BF; Cardona K; Russell MC; Staley CA; Farris AB; Maithel SK
J Surg Oncol; 2014 Feb; 109(2):61-6. PubMed ID: 24122802
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
Dominguez C; Rosa M; George TB; Pimiento J; Lauwers GY; Coppola D
Anticancer Res; 2018 Jan; 38(1):367-372. PubMed ID: 29277796
[TBL] [Abstract][Full Text] [Related]
14. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer.
Grávalos C; Gómez-Martín C; Rivera F; Alés I; Queralt B; Márquez A; Jiménez U; Alonso V; García-Carbonero R; Sastre J; Colomer R; Cortés-Funes H; Jimeno A
Clin Transl Oncol; 2011 Mar; 13(3):179-84. PubMed ID: 21421462
[TBL] [Abstract][Full Text] [Related]
16. HER2 status in Gastric and Gastroesophageal Junction Adenocarcinoma.
Rima FA; Hussain M; Haque N; Dewan RK; Rahman N; Jinnah MA; Jeba R; Chowdhury F
Mymensingh Med J; 2017 Apr; 26(2):372-379. PubMed ID: 28588175
[TBL] [Abstract][Full Text] [Related]
17. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
18. Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer-Results from the AGMT GASTRIC-5 Registry.
Huemer F; Weiss L; Regitnig P; Winder T; Hartmann B; Thaler J; Piringer G; Schmitt CA; Eisterer W; Gänzer H; Wüstner A; Andel J; Jagdt B; Ulmer H; Greil R; Wöll E
J Clin Med; 2020 Mar; 9(4):. PubMed ID: 32235305
[TBL] [Abstract][Full Text] [Related]
19. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.
Wang T; Hsieh ET; Henry P; Hanna W; Streutker CJ; Grin A
Hum Pathol; 2014 May; 45(5):970-5. PubMed ID: 24656529
[TBL] [Abstract][Full Text] [Related]
20. A survival guide to HER2 testing in gastric/gastroesophageal junction carcinoma.
Subasinghe D; Acott N; Kumarasinghe MP
Gastrointest Endosc; 2019 Jul; 90(1):44-54. PubMed ID: 30928424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
